# Sham

> Sham is a VC fund in Lyon backing Medical Device and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lyon, France
- Total investments: 11
- Last investment: May 2022
- Lead investor: 18%
- Last updated: Aug 2026
- Website: http://www.sham.fr/

Sham is a mutual insurance company that provides medical malpractice insurance in France.

## Contacts

5 contacts available for Sham. Shizune tracks 1 team members at Sham. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/societe-hospitaliere-d-assurances-mutuelles-sham?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 7 | 64% |
| Health Care | 6 | 55% |
| Biotechnology | 5 | 45% |
| Medical | 4 | 36% |
| Software | 2 | 18% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 55% |
| Venture - Series Unknown | 2 | 18% |
| Seed | 1 | 9% |
| Series A | 1 | 9% |
| Series C | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 10 | 91% |
| United States | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ramon Maluenda | Operations manager | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Therapixel | Therapixel develops and commercializes AI-based software for breast cancer detection and characterization | $15.6M | Series B | May 12, 2022 |  |
| Germitec SAS | Germitec is a healthcare company that designs, Commercialize UV-C disinfection systems for hospital hygiene system. | $11.6M | Venture - Series Unknown | May 10, 2022 |  |
| Cairdac | Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation. | $18.8M | Series A | Mar 31, 2022 |  |
| Amolyt Pharma | Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $80M | Series B | Sep 16, 2021 |  |
| Keenturtle | Keenturtle is a medtech that provides e-health solutions to enhance medical & economic field such as provision of health data. | $1.8M | Venture - Series Unknown | Aug 02, 2021 |  |
| Coave Therapeutics | Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $38.9M | Series B | Jul 21, 2021 |  |
| Mablink Bioscience | Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC). | $4.8M | Seed | Apr 27, 2021 |  |
| CyberMDX | CyberMDX is an IOT security leader dedicated to protecting the quality care of health delivery worldwide. CyberMDX provides cloud-based cybersecurity solutions that support the advancement of The Internet of Medical Things. The CyberMDX solution identifies endpoints and assesses vulnerabilities to detect, respond to, and prevent cyber incidents.Deployed worldwide, CyberMDX is designed to integrate with our customers' existing environments through its scalable, easy-to-deploy and agentless solution. | $20M | Series B | Apr 07, 2020 |  |
| EyeTechCare | EyeTechCare has developed a new medical device called EyeOP1. This leading edge technology device is the result of several years of joint research with INSERM which has led to the development of a treatment method using High Intensity Focused Ultrasound (HIFU).EyeOP1 is an ultrasound device which offers a non-invasive treatment for refractoryglaucoma. This new method is extremely accurate, simple and only takes one minute. | $11M | Series C | Mar 12, 2013 |  |
| Biom'Up | Biom'Up, expert in the field of resorbable biomaterials, designs, develops and manufactures unique medical devices based on collagen technology. These innovative and clinically proven products cover many different surgical specialties - orthopaedics, spinal, cardiac, general and maxillo-facial - and improve patient healing by allowing guidedregeneration of soft tissues and bone. | $7.5M | Series B | Oct 26, 2012 |  |

10 of 11 investments shown.

## Co-investors
- [Sham Innovation Santé](https://shizune.co/investors/profile/sham-innovation-sant%C3%A9) — VC Fund, 7 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 3 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Elaia](https://shizune.co/investors/profile/elaia-partners) — VC Fund, 2 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Sham invest in?

Sham invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series B and Venture - Series Unknown stage. Most of the 11 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Sham?

Public channels for Sham include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sham?

The team at Sham includes Ramon Maluenda (Operations manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co